Search details
1.
A monocentric phase I study of vemurafenib plus cobimetinib plus PEG-interferon (VEMUPLINT) in advanced melanoma patients harboring the V600BRAF mutation.
J Transl Med
; 19(1): 17, 2021 01 06.
Article
in English
| MEDLINE | ID: mdl-33407577
2.
Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients.
J Transl Med
; 18(1): 121, 2020 03 11.
Article
in English
| MEDLINE | ID: mdl-32160899
3.
Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumab.
J Transl Med
; 15(1): 244, 2017 12 04.
Article
in English
| MEDLINE | ID: mdl-29202855
4.
Vemurafenib beyond progression in a patient with metastatic melanoma: a case report.
Anticancer Drugs
; 26(4): 464-8, 2015 Apr.
Article
in English
| MEDLINE | ID: mdl-25622086
5.
Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma.
Cancer Immunol Immunother
; 63(7): 675-83, 2014 Jul.
Article
in English
| MEDLINE | ID: mdl-24695951
6.
The role of MEK inhibitors in the treatment of metastatic melanoma.
Curr Opin Oncol
; 26(2): 196-203, 2014 Mar.
Article
in English
| MEDLINE | ID: mdl-24419498
7.
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013.
J Transl Med
; 12: 277, 2014 Oct 28.
Article
in English
| MEDLINE | ID: mdl-25348889
8.
Novel approaches in melanoma prevention and therapy.
Cancer Treat Res
; 159: 443-55, 2014.
Article
in English
| MEDLINE | ID: mdl-24114495
9.
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial.
Nat Commun
; 15(1): 146, 2024 Jan 02.
Article
in English
| MEDLINE | ID: mdl-38167503
10.
Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".
J Transl Med
; 11: 137, 2013 Jun 03.
Article
in English
| MEDLINE | ID: mdl-23731854
11.
Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial.
J Clin Oncol
; 41(2): 212-221, 2023 01 10.
Article
in English
| MEDLINE | ID: mdl-36049147
12.
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use.
J Transl Med
; 10: 107, 2012 May 28.
Article
in English
| MEDLINE | ID: mdl-22640478
13.
The role of BRAF V600 mutation in melanoma.
J Transl Med
; 10: 85, 2012 Jul 09.
Article
in English
| MEDLINE | ID: mdl-22554099
14.
Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011".
J Transl Med
; 10: 83, 2012 Jul 04.
Article
in English
| MEDLINE | ID: mdl-22551296
15.
New-generation anticancer drugs and medication-related osteonecrosis of the jaw (MRONJ): Late onset 3 years after ipilimumab endovenous administration with a possible role of target therapy.
Clin Case Rep
; 9(1): 61-66, 2021 Jan.
Article
in English
| MEDLINE | ID: mdl-33489133
16.
Ipilimumab and Stereotactic Radiosurgery with CyberKnife® System in Melanoma Brain Metastases: A Retrospective Monoinstitutional Experience.
Cancers (Basel)
; 13(8)2021 Apr 13.
Article
in English
| MEDLINE | ID: mdl-33924595
17.
Immunotherapy in metastatic melanoma: a novel scenario of new toxicities and their management.
Melanoma Manag
; 6(4): MMT30, 2019 Nov 08.
Article
in English
| MEDLINE | ID: mdl-31871619
18.
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
J Immunother Cancer
; 7(1): 91, 2019 03 29.
Article
in English
| MEDLINE | ID: mdl-30925943
19.
Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway.
Cancer Immunol Res
; 7(5): 841-852, 2019 05.
Article
in English
| MEDLINE | ID: mdl-30940644
20.
PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab.
Oncoimmunology
; 7(12): e1405206, 2018.
Article
in English
| MEDLINE | ID: mdl-30524879